Advertisement

Neuroradiology

, Volume 48, Issue 3, pp 190–195 | Cite as

A failure of matrix metalloproteinase inhibition in the prevention of rat intracranial aneurysm formation

  • T. J. KaufmannEmail author
  • W. F. Marx
  • D. F. Kallmes
Interventional Neuroradiology

Abstract

We tested the hypothesis that nonspecific matrix metalloproteinase (MMP) inhibition with doxycycline would decrease the incidence of intracranial aneurysm formation in a rat aneurysm model. We performed common carotid artery ligation on 96 Long-Evans rats. A treatment group of 48 animals was chosen at random to receive oral doxycycline (3 mg/kg) in addition to standard rat chow, and the control group of 48 animals received standard rat chow only. The major circle of Willis arteries was dissected at 1 year following carotid ligation, and the proportions of animals with aneurysms were compared between groups using Fisher’s exact test. Four animals given oral doxycycline and ten control animals expired before 1 year. Of the examined animals, eight saccular intracranial aneurysms were found in 8 of 45 animals which had received doxycycline (17.8%) and seven saccular intracranial aneurysms were found in 7 of 37 control animals (18.9%). There was no significant difference in aneurysm formation between the doxycycline-treated and control groups (P=0.894). Nonspecific MMP inhibition with doxycycline is not effective in preventing intracranial aneurysm formation in a rat model.

Keywords

Intracranial aneurysm Animals Matrix metalloproteinases 

Notes

Acknowledgements

A Radiological Society of North America Research Resident Grant supported this work. This work was performed in the Department of Radiology, University of Virginia, Charlottesville, VA, USA. We sincerely thank Kevin S. Lee, Ph.D., University of Virginia, for invaluable advice and assistance in perfusion-fixation.

References

  1. 1.
    Annabi B, Shedid D, Ghosn P, Kenigsberg RL, Desrosiers RR, Bojanowski MW, Beaulieu E, Nassif E, Moumdjian R, Beliveau R (2002) Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms. J Vasc Surg 35:539–546PubMedCrossRefGoogle Scholar
  2. 2.
    Baxter BR, Pearce WH, Waltke EA, Littooy FN, Hallett JW, Kent KC, Upchurch GR, Chaikof EL, Mills JL, Fleckten B, Longo GM, Lee JK, Thompson RW (2002) Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg 36:1–12PubMedCrossRefGoogle Scholar
  3. 3.
    Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM (2002) Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 160:1089–1095PubMedGoogle Scholar
  4. 4.
    Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G, Franklin DP, Youkey JR (1999) The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg 29:130–138PubMedCrossRefGoogle Scholar
  5. 5.
    Boyle JR, McDermott E, Crowther M, Wills AD, Bell PR, Thompson MM (1998) Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg 27:354–361PubMedCrossRefGoogle Scholar
  6. 6.
    Bruno G, Todor R, Lewis I, Chyatte D (1998) Vascular extracellular matrix remodeling in cerebral aneurysms. J Neurosurg 89:431–440PubMedCrossRefGoogle Scholar
  7. 7.
    Coutard M, Osborn-Pellegrin M (1997) Genetic susceptibility to experimental cerebral aneurysm formation in the rat. Stroke 28:1035–1042PubMedGoogle Scholar
  8. 8.
    Crowther M, Goodall S, Jones JL, Bell PRF, Thompson MM (2000) Localization of matrix metalloproteinase 2 within the aneurysmal and normal aortic wall. Br J Surg 87:1391–1400PubMedCrossRefGoogle Scholar
  9. 9.
    Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW (1998) Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 28:1082–1093PubMedCrossRefGoogle Scholar
  10. 10.
    Curci JA, Mao D, Bohner DG, Allen BT, Rubin BG, Reilly JM, Sicard GA, Thompson RW (2000) Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg 31:325–342PubMedCrossRefGoogle Scholar
  11. 11.
    Davis V, Persidskaia R, Baca-Regen L, Itoh Y, Nagase H, Persidsky Y, Ghorpade A, Baxter BT (1998) Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 18:1625–1633PubMedGoogle Scholar
  12. 12.
    Franklin IJ, Harley SL, Greenhalgh RM, Powell JT (1999) Uptake of tetracycline by aortic aneurysm wall and its effect on inflammation and proteolysis. Br J Surg 86:771–775PubMedCrossRefGoogle Scholar
  13. 13.
    Gaetani P, Tartara F, Grazioli V, Tancioni F, Infuso L, Rodriguez y Baena R (1998) Collagen cross-linkage, elastolytic and collagenolytic activities in cerebral aneurysms: a preliminary investigation. Life Sci 63:285–292PubMedCrossRefGoogle Scholar
  14. 14.
    Gaetani P, Rodriguez y Baena R, Tartara F, Messina AL, Tancioni F, Schiavo R, Grazioli V (1999) Metalloproteases and intracranial vascular lesions. Neurol Res 21:385–390PubMedGoogle Scholar
  15. 15.
    Kaito K, Urayama H, Watanabe G (2003) Doxycycline treatment in a model of early abdominal aortic aneurysm. Surg Today 33:426–433PubMedCrossRefGoogle Scholar
  16. 16.
    Kim SC, Singh M, Huang J, Prestigiacomo CJ, Winfree CJ, Solomon RA, Connolly ES (1997) Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery 41:642–646PubMedCrossRefGoogle Scholar
  17. 17.
    Knox JB, Sukhova GK, Whittemore AD, Libby P (1997) Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 95:205–212PubMedGoogle Scholar
  18. 18.
    Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110:625–632PubMedCrossRefGoogle Scholar
  19. 19.
    McMillan WD, Patterson BK, Keen RR, Pearce WH (1995) In situ localization and quantification of seventy-two-kilodalton type IV collagenase in aneurysmal, occlusive, and normal aorta. J Vasc Surg 22:295–305PubMedCrossRefGoogle Scholar
  20. 20.
    Moore G, Liao S, Curci JA, Starcher BC, Martin RL, Hendricks RT, Chen JJ, Thompson RW (1999) Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). J Vasc Surg 29:522–532PubMedCrossRefGoogle Scholar
  21. 21.
    Newman KM, Jean-Claude J, Li H, Scholes JV, Ogata Y, Nagase H, Tilson MD (1994) Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg 20:814–820PubMedGoogle Scholar
  22. 22.
    Peters DG, Kassam A, St Jean PL, Yonas H, Ferrell RE (1999) Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 30:2612–2616PubMedGoogle Scholar
  23. 23.
    Petersen E, Wagberg F, Angquist KA (2002) Proteolysis of the abdominal aortic aneurysm wall and the association with rupture. Eur J Vasc Endovasc Surg 23:153–157PubMedCrossRefGoogle Scholar
  24. 24.
    Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW (1996) Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 23:336–346PubMedCrossRefGoogle Scholar
  25. 25.
    Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW (2000) Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105:1641–1649PubMedCrossRefGoogle Scholar
  26. 26.
    Thompson RW, Baxter BT (1999) MMP inhibition in abdominal aortic aneurysms—rationale for a prospective randomized clinical trial. Ann N Y Acad Sci 878:159–178PubMedCrossRefGoogle Scholar
  27. 27.
    Todor DR, Lewis I, Bruno G, Chyatte D (1998) Identification of a serum gelatinase associated with the occurrence of cerebral aneurysms as pro-matrix metalloproteinase-2. Stroke 29:1580–1583PubMedGoogle Scholar
  28. 28.
    Treharne GD, Boyle JR, Goodall S, Loftus IM, Bell PR, Thompson MM (1999) Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br J Surg 86:1053–1058PubMedCrossRefGoogle Scholar
  29. 29.
    Yamashita A, Noma T, Nakazawa A, Saito S, Fujioka K, Zempo N, Esato K (2001) Enhanced expression of matrix metalloproteinase-9 in abdominal aortic aneurysms. World J Surg 25:259–265PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Department of RadiologyMayo Clinic and FoundationRochesterUSA
  2. 2.Asheville Radiology AssociatesAshevilleUSA

Personalised recommendations